Antiviral Combination Therapies Market Size, Growth, Report 2022-2030

According to latest report, the global antiviral combination therapies market value was reached at US$ 42.85 billion in 2021 and projected to hit US$ 71.2 billion by 2030 with expanding CAGR of 5.8% from 2022 to 2030. 

Antiviral combination therapies are drugs developed using a combination of two or more drugs for the treatment of various viral diseases, including chronic hepatitis B, hepatitis C, and HIV. Combination antiretroviral therapy aids in stopping the virus from making multiple copies of itself in the body.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38190

The global antiviral combination therapies market is driven by significant growth in spending on research & development by market players for the development of effective antiviral combination therapies for the treatment of a range of viral diseases; ability of the combination therapy to control the antibiotic resistance, and increase in focus on drug repurposing and vaccine development for the treatment of COVID-19.

Scope of The Report

Multiple Antiviral Drugs Prove More Effective in Treatment of COVID-19 than Single Drugs

The triple combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b holds promising potentials in the treatment of coronavirus (COVID-19). Researchers in healthcare companies and organizations are referring historical findings of the lopinavir-ritonavir & ribavirin combination, which was effective in lowering the morbidity and mortality rate of the then SARS (Severe Acute Respiratory Syndrome). Since COVID-19 is a novel viral infection, companies in the antiviral combination therapies market are increasing their research in triple combination therapies to advance in the coronavirus treatment.

Many Coronavirus patients are in need for intensive respiratory support in hospitals. Since lopinavir–ritonavir and interferon beta-1b were found to reduce the viral load in SARS, companies in the antiviral combination therapies market are increasing focus in these drugs to innovate in antiviral drugs for coronavirus. It has been found that multiple antiviral drugs help to improve patient outcomes as compared to the consumption of single drug treatments.

Strategic Collaborations Help Increase Combination Therapy Trials for Combating Coronavirus

Companies in the antiviral combination therapies market are taking giant strides by increasing their trails to combat COVID-19. The Indian Institute of Chemical Technology (IICT) has joined forces with the Indian subsidiary of global pharmaceutical company, Mylan, to innovate in combination therapies for coronavirus. Many pharmaceutical companies in India have entered the Phase 3 of clinical trials with the help of computational modelling of molecules and laboratory-based data. The unprecedented demand for antiviral drugs has fueled innovations in combination therapy trials. Moreover, rising COVID-19 cases in India is acting as a key driver for market growth.

Medical institutes are increasing efforts to collaborate with hospitals to innovate in combination therapy trials. It has been found that the combination of antiviral drugs with antibiotics holds promising potentials in minimizing coronavirus symptoms in patients.

Traditional Chinese Medicine with Entecavir Reduces Morbidity in Hepatitis B Patients

The antiviral combination therapies market is projected to advance at a high CAGR during the assessment period. Healthcare companies are exploring new therapy avenues such as the combined therapy of traditional Chinese medicine (TCM), along with antiviral drugs for the treatment of chronic hepatitis B (CHB). The Chinese YinQiSanHuang-antiviral decoction with entecavir is gaining popularity for reducing the annual incidence of liver fibrosis/cirrhosis amongst hepatitis B patients. Thus, analysts of Transparency Market Research (TMR) anticipate that the antiviral combination therapy is a fast growing phenomenon for hepatitis B treatment.

It has been found that conventional antiviral drugs alone are not enough for the efficacious hepatitis B treatment. As such, there is a need for credible clinical evidence to understand the combination of TCM and Western medicines for the hepatitis B treatment.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38190

Small Molecule Antagonists Combined with Oral Antivirals for Hepatitis Treatment

The combination therapy with lamivudine or tenofovir and pegylated interferon (PEG-IFN) has been reported for the treatment of hepatitis B. As such, there is a need for clarification on clinical evidence to analyze the long-term efficacy of this type of combination therapy for CHB. Hepatitis B patients with low hepatitis B surface antigen (HBsAg) levels are being recommended with the combination therapy. However, the scientific community is faced with challenges such as restrictions in research project funds, which breaks the long-term continuity of trial periods. Hence, companies in the antiviral combination therapies market should increase their research expenditure to explore new combination therapies based on different mechanisms.

New drug developments are in pipeline for companies in the antiviral combination therapies market. In November 2018, Gilead Sciences— the U.S. biopharmaceutical company, announced that combination of GS-9688— an investigational oral selective small molecule agonist and oral antivirals is well tolerated among viral hepatitis patients.

Report Highlights

• North America dominated the global antiviral combination therapies market in 2021. The U.S. was a major market for antiviral combination therapies in the region in 2021. The expansion of the market in the country can be attributed to the presence of leading players, rise in usage of antiviral combination therapies for treating viral diseases, strong pipeline of drugs, and increase in research on the development of antiviral combination drugs for treatment of COVID-19.
• The antiviral combination therapies market in Asia Pacific is expected to expand at a high CAGR from 2022 to 2030 driven by developing countries such as China and India. The growth of the market in the region can be attributed to rise in prevalence of HIV in India and other countries in Asia. Additionally, increase in trials on combining antiviral drugs with HIV drugs for the treatment of patients with COVID-19 contributes to the growth of the market in the region.
• In terms of drug combination, the integrase inhibitor/NRTI segment is projected to account for a major share of the global antiviral combination therapies market during the forecast period. This can be attributed to increase in usage of this drug combination in the treatment of HIV. Additionally, patent exclusivity of these drugs drives the segment.
• In terms of indication, the global antiviral combination therapies market has been classified into HIV, hepatitis, and others. Globally, in 2021, over 38 million people lived with HIV. Of these, around 36.2 million were adults and 1.8 million were children. Additionally, over 1.7 million individuals acquired HIV in 2021. 
• Based on route of administration, the global antiviral combination therapies market has been bifurcated into oral and intravenous.
• In terms of distribution channel, the global antiviral combination therapies market has been segregated into hospital pharmacies, retail pharmacies, and others.

Key Players

The global antiviral combination therapies market is fragmented in terms of number of players. Key players operating in the global antiviral combination therapies market are Celltrion, Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Janssen Global Services, LLC (pharmaceutical companies of Johnson & Johnson), Cipla, Inc., Mylan N.V., Merck & Co., Inc., and F. Hoffmann-La Roche Ltd.

Market Segmentation

By Drug Combination

• NRTI/NNRTI
• Integrase Inhibitor/NRTI
• NRTI
• NRTI/Protease Inhibitor
• Others

By Type

• Branded
• Generic

By Indication

• HIV
• Hepatitis
• Others

By Route of Administration

• Oral
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38190

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/